ClinicalTrials.gg
CompletedNCT02999711Updated Dec 12, 2018

Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma

A Phase 1 interventional study of REGN3500 and Placebo in Asthma and Moderate Asthma, sponsored by Regeneron Pharmaceuticals. Completed at 3 sites in United Kingdom. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-12-12.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Aug 2018, 8 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Enrollment
357th of 427
23 · median 69
Started
2017
with 37 others
Phase 1
81 of 558
2 open now
Registered
323rd of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 357th largest by enrollment of the 427 interventional ones that give a count, is one of 38 that started in 2017, is one of 81 in phase 1, and was the 323rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

Purpose of this study is to assess the safety and tolerability of multiple ascending subcutaneous doses of REGN3500 to moderate asthmatics.

03

Conditions studied

  • Asthma
  • Moderate Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18 to 32 kg/m2
  • A diagnosis of moderate asthma (according to GINA 2015) for a period of at least 2 years prior to screening.
  • Patient must use a stable medium daily dose level of inhaled (ICS) as defined by GINA guidelines, ie, total daily dose of ICS >400 μg and ≤800 μg/day of budesonide or equivalent for at least 1 month prior to screening and during the study
  • A pre-bronchodilator forced expiratory volume in the first sec () ≥60% and ≤90% of the predicted normal values at screening and pre-dose at screening
  • A documented positive response to the reversibility test at the screening, defined as improvement in FEV1 ≥12% and ≥200 mL over baseline after 400 μg salbutamol Pmdi
  • Willing and able to comply with clinic visits and study-related procedures
  • Provide signed .

Key Exclusion Criteria:

  • abnormal CBC, clinical chemistry, and urine analysis at screening.
  • Treatment with an drug within 8 weeks or within 5 half-lives (if known), whichever is longer, prior to screening.
  • History of life-threatening asthma
  • Occurrence of asthma exacerbations or respiratory tract infections within 4 weeks prior to screening.
  • Diagnosis of any other airway/pulmonary disease such as (COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD 2016); or other lung diseases (eg, emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency or restrictive lung disease).
  • Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 1 month prior to screening.
  • Use of oral antibiotics/anti-infectives within 2 weeks prior to screening.
  • Known sensitivity to doxycycline or tetracyclines, or to any of the components of the investigational product formulation.
  • Recent (within the previous 2 months) bacterial, protozoal, viral, or parasite infection.
  • History of tuberculosis or systemic fungal diseases
  • Patients treated with a monoclonal antibody based therapy (such as an anti-IgE, anti-IL-5), a biologic therapy or immunotherapy (subcutaneous immunotherapy [SCIT], sublingual immunotherapy [SLIT], or oral immunotherapy [OIT]) in the previous 12 weeks prior to screening and during the study

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Cohort 1

    REGN3500 low dose or placebo

    Drug: REGN3500 · Drug: Placebo

  • Experimental
    Cohort 2

    REGN3500 medium dose or placebo

    Drug: REGN3500 · Drug: Placebo

Interventions

  • REGN3500 dose

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs) after repeat subcutaneous administration

    Time frame: Up to 36 weeks

  2. Severity of TEAEs after repeat subcutaneous administration

    Time frame: Up to 36 weeks

Secondary outcomes

  1. The concentration-time profile of REGN3500 after repeat subcutaneous administration

    Time frame: Up to 36 weeks

  2. Immunogenicity of REGN3500 assessed by measurement of anti-drug antibodies

    Time frame: Up to 36 weeks

  3. Percent change in total from baseline forced expiratory volume (FEV) at day 29

    Time frame: Baseline to week 4

  4. Percent change of the average of the prior 7 days of FEV1 at day 29 compared to average daily FEV1 during the last 14 days of screening

    Time frame: From -14 days screening to week 4

  5. Absolute change from baseline fractional exhaled nitric oxide (FeNO) at day 29

    Time frame: Baseline to week 4

  6. Percent change from baseline FeNO at day 29

    Time frame: Baseline to week 4

  7. Change from baseline in biomarkers at day 29

    Time frame: Baseline to week 4

  8. Percent change from baseline in biomarkers at day 29

    Time frame: Baseline to week 4

07

Study locations

3 sites
  • Regeneron Research Site
    Belfast, Northern Ireland, United Kingdom
  • Regeneron Research Site
    London, United Kingdom
  • Regeneron Research Site
    Manchester, United Kingdom
08

References and documents

Publications

  • Kosloski MP, Kalliolias GD, Xu CR, Harel S, Lai CH, Zheng W, Davis JD, Kamal MA. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials. Clin Transl Sci. 2022 Feb;15(2):384-395. doi: 10.1111/cts.13157. Epub 2021 Sep 29. PubMed 34523807 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Aug 2018, 18 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 18 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2016
First posted
Dec 21, 2016
StartActual
Feb 3, 2017
Primary completionActual
Aug 30, 2018
CompletionActual
Sep 10, 2018
Last update
Dec 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02999711
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Dec 21, 2016
Start date
Feb 3, 2017
Primary completion
Aug 30, 2018
Completion
Sep 10, 2018
Last update
Dec 12, 2018

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion